Quantitative Cancer Modeling Research Group

Staff Research Interests
Philip Hahnfeldt, Ph.D.
Principal Investigator
cancer growth dynamcis
radiotherapeutic and chemotherapeutic dosing
DNA damage and repair
tumor angiogenesis modeling
gene interaction networks
Lynn Hlatky, Ph.D.
cell-cell interactions
self-organization and emergence
stability criteria for interaction subpopulations
evolutionary dynamics
Heiko Enderling, Ph.D.
Associate Investigator
cellular automaton models
basic cancer cell kinetics in tumor dormancy and progression
cancer stem cell and progenitor dynamics
tumor morphological evolution
invadopodia formation and cancer-microenvironment interaction
tissue architecture evolution and wound healing
Xuefeng (Ryan) Gao, Ph.D.
Postdoctoral Fellow
modeling tumor growth, tumor angiogenesis, and invasion
Darwin evolution of cancer cells: the emergence and distribution of cancer cell phenotypes
modeling cancer gene therapies (e.g., virotherapy, bacterial therapy)
Charles Morton, Ph.D.
Postdoctoral Fellow
mathematical modeling of the tumor-microenvironment milieu
Kathleen Wilkie, Ph.D.
Research Associate
cell adhesion and the extracellular matrix
tissue-matrix remodelling
the effects of mechanical stresses on cells
heterogeneous cell populations in cancer progression
growth, development, and aging effects on biological tissues
mechanical properties of biological tissues
Rainer Sachs, Ph.D.
Associate Investigator
radiation induced carcinogenesis
cosmic radiation risk estimation for astronauts
second cancers after radiotherapy
radiation induced chromosome aberrations

 

Mathematical research at the CCSB

quantitative_modeling embraces the principle that cancer is not just a disease of cells but is facilitated at the population and inter-tissue levels. Accordingly, a multi-level approach must be implemented to fully understand its origin and course. Initial events in carcinogenesis occur within cells at the molecular level as repair and proliferation dysfunctions, leading to genomic instability, aneuploidy and final transformation. But after cancer cell creation, the clone advances to encounter additional molding and fate-determining events defined by cell-cell interactions. The associated stroma (fibroblasts and extracellular matrix) plays a critical role in cancer progression, as does induced tumor vascularization (angiogenesis). Both act to determine whether a nascent cancer advances to become symptomatic disease. Without stromal activation and angiogenesis, tumor development is halted early. Under NASA Specialized Centers of Research (NSCOR) funding, these studies are focusing on the determination of cancer risk to astronauts who will be exposed to harmful solar particle events (SPEs) and galactic cosmic radiations (GCRs) during long-term space flight. By extension we hope to better understand the carcinogenesis process more generally, and discover new therapeutic interventions for improved cancer treatment.

The origin of cancer may be attributed to events that alter the repair machinery of the cell and destabilize its genome. Of active interest in this regard is how nucleotide-level DNA damage and repair translates into chromosome aberrations, as chromosome-level misrepair is the feature most closely identified with carcinogenic transformation. By developing a revised theory for double-strand break repair/misrepair following ionizing radiation, we have found it possible to improve upon the commonly-accepted repair models. Starting from carcinogenesis-initiating lesions to DNA, we have gone on to link this action to the first population-level bottleneck to the growth of the resultant hyperplastic clones - self-limited cell growth. The resulting deterministic model for early carcinogenesis has proven to be competitive with the current stochastic standard in explaining major epidemiological data sets on radiation-induced carcinogenesis.

A second bottleneck encountered early in carcinogenesis is nutrient availability. Without angiogenesis, a tumor cannot grow beyond approximately 1mm in size. This obstacle to tumor growth requires the development of angiogenic potential within the growing clone of tumor cells - an 'angiogenic switch'. Interestingly, it was discovered quite by accident some time ago while performing autopsies on adults who died of non-cancer causes (Black and Welch 1993), that most middle-aged people harbor dormant, non-threatening cancer lesions. Held back by the failure to initiate angiogenesis, the tumors remained harmless throughout these individuals' lifetimes. One major objective of our Center is to understand how such a stasis may be maintained, and perhaps re-established as part of a novel therapeutic approach. We have made inroads into quantitatively understanding this natural control in tumor growth, and how antiangiogenic therapy might best be applied to achieve this goal.

Basic cell kinetics, cancer stem cells and tumor morphology.

self-metastases Tumors are intrinsically heterogeneous. The majority of the tumor cells have limited life span and replicative potential, and only a small minority (so-called cancer stem cells) live forever, divide infinitely and potentially produce more such stem cells. It is these stem cells that determine tumor formation, and their dynamics is counterintutively inhibited by their non-stem progeny. Only a high migration rate can liberate stem cells and enable their migration to seed new clones in the vicinity of the original cluster. In this manner, the tumour continually 'self-metastasises'.
We use cellular automaton models to define the behavior of single cells, and then let single cells populate a compuational domain. As the number of cancer cell increases over time competition for environmental resources (such as space) defines population dynamics. A result is a cancer cell population (a tumor) growing sub-exponentially. Tumor progession is dictated by the ability of stem cells to form self-metastases that together form a malignant invasive morphology.

Modeling DNA damage and repair, and chromosome geometry.

dna damage The chromosome damage/repair studies have interrelated results on cytogenetics and interphase chromosome localization and geometry. By developing a revised theory for double-strand break repair/misrepair following ionizing radiation,we found it possible to improve upon the commonly-accepted repair models, in the process obtaining information on how chromosomes are packaged within the nucleus. Incomplete exchange models developed from these studies were also able to explain the relation between acentric and dicentric counts and the excess dispersion (variance/mean) for the number of acentric fragments relative to dicentrics seen in human lymphocytes exposed to various radiation types and doses.

Angiogenesis modeling and anti-angigenic therapy.

self metastases Extending from collaboration with the late Dr. Judah Folkman of Children's Hospital, Boston, we are exploring the unique tumor/vascular regression kinetics of anti-angiogenic therapy. The indirect means by which tumor suppression is here accomplished, coupled with the recent finding that tumors both stimulate and inhibit their own vascularization, points to a need to formulate tumor-vascular models that properly capture the dynamics. We use sets of differential equations that simultaneously consider vascular response to anti-angiogenic agents and subsequent suppression of tumor growth. The result is a formalism that is proving to be both explanatory and clinically predictive. This work is an example of quantitative translational research, a "workstation-to-bench-to-bedside" research strategy embraced by the CCSB. An important dynamic to surface from these studies is the self-imposed Gompertz restriction on growth imposed by a tumor on itself. Implications for the general organogenic control of tissue mass are suggested. Another study of dose rate effects addresses an as yet un-quantified effect -- the utility of so-called "metronomic" (small, evenly-spaced) dosing on the treatment response of a tumor population. It was shown considering the response of a heterogeneous target to various dosing protocols that: 1) metronomic dosing does indeed offer the best tumor suppression, and 2) the shift to metronomic dosing from more traditional "up-front" dosing regimens favors the endothelial cell compartment. The theory offers one explanation for numerous reports of an antiangiogenic response using the metronomic scheme.

Tumor heterogeneity.

tumor heterogeneity A unifying theme in both the DNA repair and angiogenesis studies is the role tumor heterogeneity and inter-tissue interactions play in carcinogenesis risk and cancer treatment response. Under our NASA NSCOR Program Project dedicated to examining how inter-cellular interactions modulate carcinogenesis, we are currently employing quantitative methods to understand the unifying mechanisms more precisely. A deterministic carcinogenesis risk model that incorporates cell-cell interactions was developed which compares favorably to the current stochastic model standard in explaining epidemiologic data on atom bomb survivors. Additional unpublished studies are now showing that inter-cellular interactions may even decide the course of cancer after the fact of tumor cell creation, proving these interactions to be a vital augment to current cell-centric focuses on cancer origin and treatment response.

 

Representative publications: